Drug intelligence / Profile preview

COL-121

Development stage: Phase 2
Lead developer: Deltanoid Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

COL-121 is a novel vitamin D analog developed by Deltanoid Pharmaceuticals for the treatment of plaque-type psoriasis. It is designed to provide anti-psoriatic effects similar to earlier vitamin D analogs like calcipotriol, but with an improved safety profile, specifically aiming to eliminate the adverse effects of hypercalcemia and hypercalciuria. The drug is also intended to be more stable and easier to administer than previous generations of vitamin D analogs.

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on COL-121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COL-121.

Explore the full profile